University of Osaka Researchers Discover iTab Antibodies Capable of Selectively Suppressing Autoimmune Disease Immune Responses

University of Osaka researchers discover iTab antibodies that selectively suppress overactive T cells, offering hope for targeted autoimmune disease therapies.

By: AXL Media

Published: Apr 23, 2026, 6:32 AM EDT

Source: Information for this report was sourced from EurekAlert!

Identifying a New Shield Against Autoimmunity

The complex machinery of the human immune system, while essential for fighting pathogens, occasionally malfunctions by targeting healthy tissue. This biological error is the root cause of autoimmune conditions like multiple sclerosis. However, researchers at The University of Osaka have uncovered a previously hidden regulatory mechanism that the body uses to calm these self-destructive impulses. By discovering a specific type of antibody that can physically block the activation of aggressive T cells, the team has identified a potential pathway for treating autoimmune disorders without compromising the patient’s overall ability to fight infections.

The Discovery of TCR-Like Antibodies

At the center of this breakthrough is a novel antibody classified as an "immune-induced TCR-like antibody," or iTab. Lead author Kazuki Kishida explains that these iTabs function by mimicking the receptors found on T cells. In a healthy immune response, T cells must "plug in" to MHC class II molecules to recognize threats. The iTabs intervene by latching onto these molecules first, effectively acting as a biological cap that prevents the T cell from ever becoming activated. This selective interference ensures that the immune response is shut down at its source before it can damage healthy cells.

Mechanism of Antigen Recognition

The research team utilized mouse models to determine exactly how the immune system decides to produce these protective iTabs. They found that the production of these antibodies is triggered when antigens—the protein fragments that T cells scan for—contain specific extra segments known as flanking regions. When the immune system encounters these specific protein structures, it generates iTabs to bind them. This discovery suggests that the body possesses an innate ability to recognize when an immune response might be unnecessary or harmful, producing iTabs as a localized "off switch" to maintain internal balance.